We will investigate the effects of high dairy intake on metabolic flexibility, glucose metabolism and insulin sensitivity, which are all important characteristics of (metabolic) health. We hypothesize that high dairy intake improves insulin…
ID
Bron
Aandoening
Insulin resistance, Type 2 Diabetes Mellitus, metabolic health.
Insuline resistentie, Type 2 Diabetes Mellitus, metabole gezondheid.
Ondersteuning
Project: ‘Basisvoedingsmiddelen- en gedragsinterventies in relatie tot behoud van gezondheid’ (TKI-AF-12104)
Partners deelproject ao UMCG, FrieslandCampina.
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
As an indicator of metabolic flexibility the change in RQ (ÄRQ) during each challenge test (OGTT and subsequent fasting) will be measured during the test day (wk 6). This parameter relates to the change in substrate oxidation (fatty acids vs. glucose).
Achtergrond van het onderzoek
This study aims to investigate the effect of high versus low dairy intake on metabolic fexibility, insulin sensitivity and glucose metabolism in middle-aged, overweight individuals.
Doel van het onderzoek
We will investigate the effects of high dairy intake on metabolic flexibility, glucose metabolism and insulin sensitivity, which are all important characteristics of (metabolic) health. We hypothesize that high dairy intake improves insulin sensitivity, glucose tolerance and metabolic flexibility in a population at risk.
Onderzoeksopzet
After each 6 wk period the glucose metabolism and metabolic flexibility of the volunteers will be tested with an oral glucose challenge and a fasting period. During this day several indirect calorimetry measurements will be performed and blood samples will be collected (first every 15 min, later hourly).
Onderzoeksproduct en/of interventie
High dairy (5-6 portions/day) vs low dairy (<1 portion/day), for a 6 week period each.
Portion sizes are 250 ml for (butter)milk, 200 g for yoghurt and 30 g (one slice) of cheese.
Algemeen / deelnemers
Universitair Medisch Centrum Groningen
Interne Geneeskunde – Nefrologie
Hanzeplein 1
Groningen 9713 GZ
The Netherlands
c.eelderink@umcg.nl
Wetenschappers
Universitair Medisch Centrum Groningen
Interne Geneeskunde – Nefrologie
Hanzeplein 1
Groningen 9713 GZ
The Netherlands
c.eelderink@umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Healthy male or postmenopausal female volunteer
2. Middle-aged: between 45 and 65 yrs of age
3. BMI > 25 to < 30 kg/m2
4. Low-medium dairy consumer (based on VCP, assessed by questionnaire on health and lifestyle)
5. Used to consume 3 main meals a day including breakfast
6. Not involved in intensive sports activities more than twice a week (e.g. playing football, tennis, running, race-cycling, swimming)
7. Stable weight and no intention to lose weight until completion of the study
8. Able to participate and willing to comply with study procedures and restrictions
9. Signed written informed consent form (ICF)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Diabetes mellitus (based on fasting glucose and HbA1c-values at screening)
2. Clinically relevant abnormalities in blood lipids (total cholesterol > 8 mmol/L, triglycerides > 6 mmol/L, LDL > 5.7 mmol/L) at screening
3. Clinically relevant abnormalities in hematology (a.o. Hb < 8,7 mmol/L) at screening
4. Clinically relevant abnormalities in markers for liver (ALAT, ASAT) and kidney (creatinine-albumin ratio, urine) damage at screening
5. Positive HIV, HbsAg and/or HepC at screening
6. Not being able to fast overnight (12 hours)
7. Unable to resign from smoking during test day (12h) without symptoms of withdrawal
8. Gastrointestinal disorders or undergone digestive tract surgery (except appendectomy)
9. Intake of nutritional supplements (from screening until the end of the study)
10. Use of medication (from screening until the end of the study) that, in the opinion of the investigator/physician, would interfere with the study parameters: oral anti-diabetics, insulin, lipid-lowering drugs (from screening until the end of the study) and anti-biotics (from 1 month before screening).
11. Reported slimming or medically prescribed diet
12. Reported vegan, vegetarian or macrobiotic life-style
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4694 |
| NTR-old | NTR4899 |
| Ander register | Protocol nr: NL2014.UMCG.N190, ABR nr: NL47643.042.14 : METc nr: METc 2014/298 |